Expert Rev Anti Infect Ther by Hurst, Stacey A. et al.
Prevention of mother-to-child transmission of Human 
Immunodeficiency Virus Type 1 (HIV): the role of neonatal and 
infant prophylaxis
Stacey A. Hurst, Kristie E. Appelgren, and Athena P. Kourtis*
Division of Reproductive Health, National Center for Chronic Disease Prevention and Health 
Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA
Summary
The prevention of mother-to-child transmission (PMTCT) of HIV is one of the great public health 
successes of the past 20 years. Much concerted research efforts and dedicated work have led to the 
achievement of very low rates of PMTCT of HIV in settings that can implement optimal 
prophylaxis. Though several implementation challenges remain, global elimination of pediatric 
HIV infection seems now more than ever to be an attainable goal. Often overlooked, the role of 
prophylaxis of the newborn is nevertheless a very important component of PMTCT. In this paper, 
we focus on the role of neonatal and infant prophylaxis, discuss mechanisms of protection, and 
present the clinical trial-generated evidence that led to the current recommendations for preventing 
infections in breastfed and nonbreastfed infants. PMTCT of HIV should not end at birth; a 
continuum of care extending postpartum and postnatally is required to minimize the risk of new 
pediatric HIV infections.
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The prevention of mother-to-child transmission (PMTCT) of Human Immunodeficiency 
Virus Type 1 (HIV) is one of the great public health successes of the past 20 years. From a 
transmission rate of 25%–42% without any interventions, the rate has now been reduced to 
1% or less in settings where the full array of prophylactic strategies can be implemented 
[201,202]. Prevention modalities include use of antiretroviral (ARV) regimens during 
pregnancy, labor and delivery, and postnatally to the infant; and elective cesarean delivery 
before amniotic membrane rupture in cases where the HIV load is still detectable in late 
pregnancy [202]. In settings where breastfeeding is the safest infant feeding option, use of 
ARV medications by the mother during the whole duration of breastfeeding is recommended 
by the World Health Organization (WHO) [201]. As a result of implementing these 
evidence-based preventive measures, fewer than 200 infants are newly infected with HIV in 
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the United States annually [203]. In less advantaged settings, however, pediatric HIV 
infection is an ongoing epidemic, and approximately 260,000 new pediatric infections were 
estimated worldwide in 2012 [204], most of them acquired through MTCT, and most of 
them in sub-Saharan Africa, where there are many challenges in implementing clinical 
practice recommendations.
Even though PMTCT of HIV should be multitargeted and encompass the following: primary 
prevention of HIV infection among young women; prevention of unintended pregnancy 
among HIV-infected women; and optimal care of the HIV-infected mothers and infants; 
PMTCT's cornerstone (and the focus of this article) is the use of ARV agents during 
gestation, labor and delivery, and postpartum or postnatally to mothers and infants. In this 
article, we will more specifically focus on the role of neonatal and infant ARV prophylaxis.
As the evidence from the research studies detailed in the following sections demonstrates, 
neonatal prophylaxis is an important component of PMTCT of HIV when the mother has 
received ARV medications antenatally, and neonatal prophylaxis is absolutely critical when 
the mother has not received ARV prophylaxis before delivering the infant. The biologic 
basis for the efficacy of neonatal prophylaxis in preventing HIV infection in the infant is 
acting as pre-exposure prophylaxis (e.g., postnatal exposure to HIV during breastfeeding), or 
as post-exposure prophylaxis (e.g., fetal or infant exposure to infectious maternal blood and 
genital secretions during late gestation and labor and delivery) [1]. Infant ARV prophylaxis 
protects against the virus, which might have obtained access to the infant's circulation 
through maternal-fetal transfusion or systemic dissemination of the virus swallowed by the 
infant during passage through the birth canal [2]. In addition, infant ARV prophylaxis can be 
beneficial when the virus remains unintegrated in quiescent cells [3], and thus, when ARV 
prophylaxis is administered right after birth, it could even provide pre-exposure prophylaxis 
for late exposures during delivery.
Overview of select important studies of ARV prophylaxis to reduce 
perinatal HIV transmission, including neonatal prophylaxis
Pediatric AIDS Clinical Trials Group (PACTG) 076 was the first seminal study that 
transformed the field of HIV prevention and the first example of use of ARV as pre-
exposure prophylaxis. The study was a randomized, double-blind, placebo-controlled trial 
[4] among HIV-infected pregnant women between 14 and 34 weeks’ gestation, with CD4 
counts higher than 200 cells/mm3, who had not received antiretroviral therapy (ART) during 
the current pregnancy. Antenatal, intrapartum, and neonatal prophylaxis components were 
all included: Women received either placebo or zidovudine (ZDV) antepartum (100 mg 
orally 5 times daily), and intrapartum (2 mg/kg of body weight given intravenously during 1 
hour, then 1 mg/kg per hour until delivery). The infant also received ZDV (2 mg/kg orally 
every 6 hours for 6 weeks beginning 8–12 hours after birth). Women in this study did not 
breastfeed their infants.
The results were dramatic. HIV transmission rates at 18 months were 8.3% among the ZDV 
group versus 25.5% among the placebo group, corresponding to a 67.5% relative reduction 
in the risk of transmission of HIV to infants. The results of this study were rapidly 
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disseminated in 1994 and adopted as the standard of care in resource-advantaged countries 
[5]. Epidemiologic data from the United States and France confirmed the regimen's 
effectiveness in decreasing perinatal HIV infection within a few years [6].
For resource-limited countries, however, the PACTG 076 regimen posed implementation 
challenges [7]. In response to this, several studies were conducted in Thailand and sub-
Saharan Africa of simplified, shorter regimens to reduce the risk of MTCT of HIV [8-12]. 
Among them, the Petra Study was a randomized, double-blind, placebo-controlled trial to 
evaluate the safety and efficacy of three short-course combination regimens of ZDV and 
lamivudine (3TC) in preventing MTCT of HIV in Tanzania, South Africa, and Uganda [12]. 
The Petra Study evaluated the relative importance of starting ARV antepartum versus 
intrapartum, and included a neonatal component. HIV-infected pregnant women were 
randomly assigned to one of four regimens: group A (antepartum oral ZDV plus 3TC twice 
daily from 36 weeks’ gestation, intrapartum oral ZDV plus 3TC, and postpartum oral ZDV 
plus 3TC twice daily to the mothers and oral ZDV plus 3TC twice daily to the infants for 7 
days); group B (the intrapartum and postpartum components of the group A regimen); group 
C (the intrapartum component of the group A regimen); or placebo. At 6 weeks, the HIV 
transmission rates were 5.7% for group A, 8.9% for group B, 14.2% for group C, and 15.3% 
for the placebo group, which corresponded to an efficacy of 63% for regimen A and 42% for 
regimen B. 74% of infants were breastfed (median duration 28 weeks). Comparing groups B 
and C, the importance of neonatal prophylaxis is self-evident, when ARV interventions are 
not initiated until the intrapartum period.
A subsequent milestone on the path of prevention of MTCT of HIV was the HIVNET 012 
study, a randomized trial comparing intrapartum and neonatal single-dose nevirapine (NVP) 
with ZDV among a breastfeeding population (99% breastfeeding with median duration of 9 
½ months) in Uganda [11,13]. HIV-infected pregnant women were randomly assigned to 
either the NVP arm (intrapartum single-dose NVP orally at onset of labor and postpartum 
single-dose NVP to the infant orally within 72 hours of birth), or to the ZDV arm 
(intrapartum ZDV orally at onset of labor and every 3 hours until delivery and to the infant 
twice daily for 7 days). HIV transmission rates at 6–8 weeks were 11.8% among the NVP 
group and 20.0% among the ZDV group, corresponding to a 42% relative reduction in the 
risk of transmission to infants in the NVP group. This regimen was a new breakthrough—a 
simple, inexpensive, and efficacious treatment that acted as both pre- and post-exposure 
neonatal prophylaxis targeted at the time of perinatal exposure because of the long half-life 
of NVP. Plans were made for widespread rollout of this regimen in Africa. However, it 
quickly became apparent that use of the single-dose NVP regimen led to the development of 
resistance to NVP and other drugs in its class [14]. Efforts to reduce NVP resistance after 
single-dose peripartum administration, which were shown effective, included the addition of 
a short “tail” regimen of ARV, such as 1 week of ZDV and 3TC [15,16], or addition of a 
single dose of tenofovir (TDF) and emtricitabine (FTC) [17].
To elucidate which prophylaxis component (maternal or neonatal) had the greatest benefit 
and what its optimal duration was, the Perinatal HIV Prevention Trial (PHPT-1), conducted 
in Thailand, compared four ZDV regimens of varying duration among mothers and infants 
in a randomized, double-blind design [18]. The maternal long regimen was oral ZDV from 
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28 weeks’ gestation and intrapartum, and the short regimen was oral ZDV from 35 weeks’ 
gestation and intrapartum. For infants, the long regimen was 6 weeks of oral ZDV, and the 
short regimen was 3 days of oral ZDV. Women agreed not to breastfeed as part of the 
inclusion criteria for the study. There were four groups in the study to evaluate the different 
combinations of long and short regimens for mothers and infants. After the first interim 
analysis, the regimen where both the mother and infant were receiving the short-course (the 
short-short regimen) was stopped because of higher rates of perinatal HIV transmission 
(10.5%) compared with the long-long regimen (4.1%). For the entire study period, the 
groups that remained open to enrollment showed equivalent efficacy (no statistically 
significant difference), with HIV transmission rates of 6.5% for the long–long regimen, 
4.7% for the long–short regimen, and 8.6% for the short–long regimen. In utero transmission 
was significantly higher with the two regimens that had shorter maternal treatment (5.1%) 
than with the two with longer maternal treatment (1.6%). With longer duration of antenatal 
ZDV, however, increasing the length of neonatal prophylaxis did not seem as important.
The Perinatal HIV Prevention Trial (PHPT-2), also conducted in Thailand, was a 
randomized, double-blind trial of three treatment regimens to evaluate the addition of single-
dose oral NVP to a standard ZDV regimen for mothers and infants [19]. For the mother, the 
standard ZDV regimen was oral ZDV from 28 weeks’ gestation through delivery. For the 
infant, standard ZDV was for 1 week after birth, unless the mother received ZDV for less 
than 4 weeks, in which case the infant was treated for 4–6 weeks. Infants were not breastfed. 
The study intervention was either addition of a single-dose of NVP to the mother and the 
infant (nevirapine-nevirapine regimen); NVP to the mother and placebo to the infant 
(nevirapine-placebo regimen); or placebo to both the mother and the infant (placebo-placebo 
regimen). At the first interim analysis, the study's Data and Safety Monitoring Board 
(DSMB) stopped enrollment in the placebo-placebo group because of higher transmission 
rates (6.3%) compared with the nevirapine-nevirapine group (1.1%). At the completion of 
the trial, there was no statistically significant difference between transmission rates in the 
nevirapine-nevirapine group (1.9%) and the nevirapine-placebo group (2.8%). However, in 
resource-rich settings that used longer combination ARV regimens during pregnancy, the 
addition of single-dose NVP during labor or delivery and to the infant did not further reduce 
MTCT [20].
Infant prophylaxis perinatally, when the mother has not received prior ARV drugs
Although the results from the PHPT-1 study showed that longer maternal regimens were 
preferred to decrease in utero transmission, it is not always possible for women to receive 
antepartum or even intrapartum prophylaxis. Neonatal prophylaxis is particularly important 
when the mother has not received ARV medications antenatally. A retrospective analysis 
using data from the New York State Department of Health showed how important early 
initiation of neonatal prophylaxis is in this scenario [21]. HIV transmission to the infant was 
6.1% when ZDV treatment was started antepartum, 10.0% when started intrapartum, 9.3% 
when started postnatally within the first 48 hours of life, and 18.4% when started on day 3 of 
life or later. The rates were all significantly lower than the rate of 26.6% in the absence of 
ZDV prophylaxis. Among those in whom treatment was started postnatally, ZDV showed 
the highest benefit, if initiated within the first 12 hours of life, with a 5.9% transmission rate 
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among this group of infants [22]. Because of the early success of the ZDV 076 regimen, and 
the subsequent studies and accumulated experience with its use, such as the study mentioned 
above, ZDV has been the mainstay of infant prophylaxis in the United States and Europe. 
Several more recent studies have investigated whether other ARV or combination regimens 
might offer advantages, particularly in settings with very high risk of transmission, such as 
when no antenatal ARV regimen had been used.
i. Among non-breastfeeding populations—HPTN 040/PACTG 1043 was a 
randomized, controlled trial of postpartum ARV regimens to prevent MTCT of HIV 
conducted in Brazil, South Africa, Argentina, and the United States [23]. Infants born to 
HIV-infected women who had not received ARV before labor were randomly assigned 
within 48 hours of birth to 1 of 3 ARV regimens: ZDV for 6 weeks; ZDV for 6 weeks plus 3 
doses of NVP during the first 8 days of life; or ZDV for 6 weeks plus nelfinavir (NFV) and 
3TC for 2 weeks. Intrapartum HIV transmission rates among infants who tested negative at 
birth were significantly lower in the ZDV plus NVP arm (2.2%) and the ZDV plus 
3TC/NFV arm (2.4%) compared with the ZDV only arm (4.8%). However, the rate of 
neutropenia was significantly increased in the ZDV plus 3TC/NFV arm. There were no 
significant differences in the distribution of resistance mutations among the groups. The 
ZDV plus NVP regimen became the new recommended regimen in the United States for 
prophylaxis of infants whose mothers had not received antenatal ARV [202].
ii. Among breastfeeding populations—The NVAZ trial conducted in Malawi 
evaluated post-exposure prophylaxis regimens given to infants of women who presented late 
for delivery (i.e., within 2 hours of expected delivery) and were confirmed to be HIV-
infected after delivery [24]. The study was a randomized, open label, controlled trial to 
determine whether prophylaxis of NVP plus ZDV given to only infants reduced 
transmission of HIV more than single-dose NVP alone (the standard of care for resource-
limited settings at the time). All infants received NVP as soon as possible after birth. Infants 
randomized to the ZDV arm also received ZDV twice daily for 1 week. Overall HIV 
transmission rates at 6–8 weeks were 15.3% among the NVP plus ZDV group and 20.9 % 
among the NVP only group. Among infants who were not HIV infected at birth, 
transmission rates at 6–8 weeks were 7.7% among the NVP plus ZDV group and 12.1% 
among the NVP only group, corresponding to a 36% relative reduction in the risk of 
transmission to infants in the NVP plus ZDV group. This study confirmed that combination 
neonatal prophylaxis was more efficacious in preventing MTCT than a single agent (in this 
case NVP) when antenatal prophylaxis had not been received. In contrast, when the mother 
had presented for delivery in time to receive HIV testing and counseling and an intrapartum 
dose of NVP, there was no statistically significant difference in perinatal HIV transmission 
rates, as seen in a study of the same two regimens in Malawi [25]. 99% of infants were 
breastfed in these two studies.
A comparison of NVP (single-dose) and ZDV (for 6 weeks) as neonatal prophylaxis for 
infants of untreated mothers was performed in a randomized trial in South Africa [26]. The 
overall results did not show a statistically significant difference in HIV transmission 
between the two groups at 12 weeks (14.3% in the NVP group and 18.1% in the ZDV 
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group). Among infants who were not infected at birth (negative HIV PCR test result at 
birth), transmission rates at 12 weeks were 7.9% in the NVP arm and 13.1% in the ZDV 
arm. After further multivariable analysis, including adjustment for breastfeeding status, it 
appeared that the 6 week ZDV regimen was not as effective as single-dose NVP in reducing 
postnatal HIV transmission. Only about 16% of the infants breastfed in this study.
Infant prophylaxis to reduce postnatal MTCT of HIV during breastfeeding
The challenge presented by transmission of HIV during breastfeeding was addressed by a 
subsequent wave of important studies. Several studies evaluated administration of ARV 
regimens to the mother during breastfeeding [27-31]. For these studies, the neonatal regimen 
used was typically NVP with or without other ARV drugs for a short duration—up to 4 
weeks. We focus here on those that evaluated neonatal or infant prophylaxis as peri-
exposure prophylaxis (PreP).
The Mashi Study conducted in Botswana was a factorial, randomized clinical trial with peri- 
partum (single-dose NVP vs placebo) and postpartum infant feeding (formula vs 
breastfeeding with infant ZDV prophylaxis) interventions [32,33]. Infants were randomized 
to 6 months of breastfeeding plus ZDV or to formula feeding plus 1 month of ZDV. The 
HIV transmission rate among the formula-fed group was significantly lower than among the 
breastfed group (5.6% vs 9.0%) at 7 months, but cumulative infant mortality was 
significantly higher among the formula-fed infants (9.3% vs 4.9%). Both strategies had 
similar cumulative mortality or HIV infection rates at 18 months; 13.9% among the formula 
fed group and 15.1% among the breastfed group. The results of this study highlighted the 
importance of breastfeeding in settings where safe infant feeding alternatives are not 
available and, consequently, of finding effective ARV strategies for use during the 
breastfeeding period.
The Six Week Extended-Dose Nevirapine (SWEN) study team reported data from three 
separate, but coordinated, randomized clinical trials conducted in Uganda, Ethiopia, and 
India to assess whether daily NVP given to breastfed infants through 6 weeks of age could 
decrease risk of HIV transmission from breastfeeding [34]. HIV-infected women and their 
infants received the standard HIVNET 012 single-dose NVP regimen [11] only or the 
standard HIVNET 012 single-dose NVP regimen plus extended-dose NVP daily to the 
infants from 8 to 42 days of age. Among infants who were HIV-uninfected at birth, there 
was a significant reduction in the risk of HIV transmission at 6 weeks in the extended-
nevirapine arm compared with the control arm, with transmission rates of 2.5% and 5.3%, 
respectively. At 6 months, however, there was no statistically significant difference between 
the two arms, with HIV transmission rates of 6.9% in the extended-nevirapine arm and 9.0% 
in the control arm, attributable to continued breastfeeding.
The Post-Exposure Prophylaxis of Infants (PEPI) trial conducted in Malawi also evaluated 
extended infant ARV prophylaxis to reduce the risk of HIV transmission from breastfeeding 
[35]. Infants were randomly assigned to one of three regimens: single-dose NVP plus 1 
week of ZDV (control regimen); the control regimen plus daily extended prophylaxis either 
with NVP (extended NVP); or with NVP plus ZDV (extended dual prophylaxis) until 14 
weeks of age. Mothers who presented to the clinic for delivery in time received intrapartum 
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single-dose NVP. The HIV transmission rate at 9 months among infants who were HIV-
uninfected at birth was significantly higher among the control group (10.6%) than among 
the extended-nevirapine (5.2%) or the extended-dual-prophylaxis (6.4%) groups. Efficacy of 
the extended NVP regimen was 67% at 14 weeks and 51% at 9 months. Efficacy of the 
extended dual prophylaxis regimen was 66% at 14 weeks and 40% at 9 months. There were 
no statistically significant differences in HIV transmission rates between the two extended 
prophylaxis groups. The extended dual prophylaxis regimen, however, was associated with 
significantly more adverse events, primarily neutropenia. Results from a follow-up analysis 
showed that at 24 months of age, HIV transmission rates were still significantly higher 
among the control group (15.6%) than among the extended-nevirapine (10.8%) or the 
extended-dual-prophylaxis (11.2%) groups, but the protective efficacy continued to decline 
after stopping prophylaxis at 14 weeks [36].
The Mitra study was an open-label, non-randomized, prospective cohort study conducted in 
Tanzania to evaluate daily 3TC given to the infant to reduce MTCT of HIV through 
breastfeeding [37]. HIV-infected pregnant women were treated according to regimen A of 
the Petra trial [12], with ZDV and 3TC from 36 weeks’ gestation to 1 week postpartum. 
Infants were treated with ZDV and 3TC from birth to 1 week of age, as in the Petra trial. In 
addition, they received 3TC during the breastfeeding period up to 6 months (median 18 
weeks). The HIV transmission rate at 6 months was 4.9% overall and 1.2% among infants 
who were HIV-uninfected at 6 weeks. The breastfeeding population in arm A of the Petra 
trial was used as the comparison group, and the results showed that the HIV transmission 
rate was more than 50% lower during breastfeeding up to 6 months after delivery in the 
Mitra Study (4.0% vs 9.9%).
The Breastfeeding, Antiretrovirals, and Nutrition (BAN) study conducted in Malawi was a 
randomized, controlled trial evaluating the safety and efficacy of a maternal triple ARV 
regimen or infant NVP prophylaxis for 28 weeks during breastfeeding to reduce postnatal 
MTCT of HIV [27]. HIV-infected breastfeeding mothers and their infants were randomly 
assigned to receive a maternal ARV regimen, infant NVP, or no extended postnatal ARV 
regimen. All mothers and infants received perinatal prophylaxis with single-dose NVP and 1 
week of ZDV plus 3TC. The extended regimens for mothers and infants began after delivery 
and continued until the cessation of breastfeeding but no longer than 28 weeks. The 
extended maternal ARV regimen consisted of ZDV, 3TC, and either NVP, nelfinavir (NFV), 
or lopinavir plus ritonavir (LPV/r). All women were counseled to exclusively breastfeed 
followed by rapid weaning between 24 and 28 weeks. The estimated risk of postnatal 
transmission at 28 weeks among infants who were HIV-uninfected at 2 weeks was 
significantly higher among the control group (5.7%) than among the maternal ARV (2.9%) 
or the infant NVP (1.7%) groups. Hypersensitivity reactions were diagnosed in 1.9% of the 
infants in the NVP group. The results of the 48-week follow-up showed that the cumulative 
risk of HIV transmission for infants HIV-uninfected at 2 weeks was still significantly higher 
among the control group (7%) than among the maternal-ARV (4%) or the infant NVP (4%) 
groups, with 30% of infections occurring after 28 weeks [38]. Preliminary analysis of NVP 
resistance among infants infected during the study shows development of resistance 
mutations in a substantial proportion of infected infants in the extended NVP group 
(manuscript in preparation). This trial was the only one to include a maternal and infant 
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ARV study arm; the results showed that the two arms had comparable efficacy. However, 
the study was not powered to examine this comparison and, interestingly, the infant NVP 
regimen was faster than the maternal ARV regimen to achieve reduction in MTCT of HIV to 
the infant among this population of women who had not received ARV medications 
antenatally.
HIV Prevention Trials Network (HPTN) 046 was a randomized, double-blind, placebo-
controlled trial conducted in South Africa, Tanzania, Uganda, and Zimbabwe to assess the 
incremental benefit of extension of an infant NVP regimen from age 6 weeks to 6 months to 
reduce the risk of postnatal MTCT of HIV [39]. After receiving NVP prophylaxis from birth 
through 6 weeks, HIV-uninfected breastfeeding infants of HIV-infected mothers were 
randomized to receive extended NVP prophylaxis or placebo until 6 months of age or until 
breastfeeding cessation, whichever came first. The postnatal transmission rate from 6 weeks 
to 6 months was significantly lower among the extended NVP arm (1.1%) than among the 
control arm (2.4%). There were no statistical differences in postnatal transmission rates 
between the study arms for the remainder of the follow-up period from age 6 months 
through 18 months, though transmission rates at 18 months were still low (2.2% in the 
extended NVP arm and 3.1% in the control arm) [40].
The ANRS 12174 Trial conducted in Burkina Faso, South Africa, Uganda, and Zambia was 
a randomized, controlled trial comparing the efficacy and safety of prolonged infant PreP 
with LPV/r or 3TC to prevent postnatal MTCT of HIV during the full duration of 
breastfeeding [41]. HIV-uninfected breastfeeding infants born to mothers not eligible for 
ART for their own health (i.e., with CD4 >350 cells/mm3) were randomly assigned to 
receive either LPV/r or 3TC. The median duration of breastfeeding was 42 weeks. At 50 
weeks, HIV transmission rates were similar with 1.4% in the LPV/r arm and 1.5% in the 
3TC arm. Both regimens were well tolerated.
WHO recommendations for prevention of MTCT of HIV
The WHO Recommendations for the use of ARV regimens for PMTCT have evolved over 
the years as new scientific and programmatic evidence became available. The feeding 
recommendations for infants of HIV-infected mothers have also changed as scientific and 
programmatic evidence became available, balancing the need to prevent MTCT of HIV 
while considering the risks associated with not breastfeeding in resource-limited settings.
The current WHO recommendations for the use of ARV regimens for PMTCT were released 
in June 2013 as part of the consolidated guidelines on the use of ARV medications for 
treating and preventing HIV infection, which combine and harmonize guidelines for ART 
among adults and adolescents, among infants and children, and for treating pregnant women 
living with HIV and preventing HIV infection in infants [201]. One of the key 
recommendations is earlier initiation of ART for all populations (CD4 count < 500 
cells/mm3). Two options are recommended for PMTCT (Table 1): (a) providing lifelong 
ARV medications to all HIV-infected pregnant and breastfeeding women regardless of CD4 
count or clinical stage (Option B+), or (b) providing ARV medications to all HIV-infected 
pregnant and breastfeeding women during the MTCT risk period and then continuing 
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lifelong ART for women eligible for treatment for their own health (Option B). For both 
options, the recommended infant prophylaxis regimen is once daily NVP for 6 weeks among 
breastfeeding infants and 4–6 weeks of once-daily NVP or twice-daily ZDV among non-
breastfeeding infants. The duration of infant ARV prophylaxis may be extended to 12 weeks 
if the mother was diagnosed with HIV infection during labor or immediately postpartum and 
she plans to breastfeed, or if the infant was identified as HIV-exposed after birth and is 
breastfeeding. In case a mother who breastfeeds interrupts her ARV regimen (because of 
toxicity, stock-outs, or if she refuses to continue), infant prophylaxis with NVP is 
recommended until 6 weeks after the maternal ARV regimen is restarted or until 1 week 
after breastfeeding has ended [201]. With regard to infant feeding, the WHO guidelines 
recommend, (in countries where national authorities have chosen to promote breastfeeding 
with an ARV intervention), that infants exclusively breastfeed for 6 months, be introduced 
to appropriate complementary foods thereafter, and continue to breastfeed for the first 12 
months of life [205]. Breastfeeding should only be stopped once a nutritionally adequate and 
safe diet without breast milk can be provided.
Though the WHO guidelines are based on the most up-to-date scientific and programmatic 
evidence, many questions remain about the long-term safety and effectiveness of the options 
for PMTCT. Promoting Maternal-Infant Survival Everywhere (PROMISE) is a combination 
of studies designed to provide answers to some of these questions [206-209]. As countries 
move to scale up interventions, more data about the feasibility of these options will become 
available.
US guidelines for the use of ARV for neonatal prophylaxis
The recommendations in resource-advantaged settings for the use of ARV for PMTCT have 
also changed over the years as treatment options for HIV-infected pregnant women have 
expanded. US guidelines will be discussed in depth as an example. There have been 
relatively few changes to the recommended regimen for prophylaxis provided to infants 
since the PACTG 076 regimen was adopted [4]. Most recently, the US guidelines were 
updated in March 2014 [202]. Selection of an ARV regimen for neonatal prophylaxis 
emphasizes the importance of classifying transmission risk by assessing maternal 
combination ART use and level of viral suppression. A 6-week course of twice daily ZDV, 
ideally started within 6–12 hours of birth, is recommended for all HIV-exposed infants. 
However, a shortened 4-week course may be considered for HIV-exposed infants at 
decreased transmission risk, (i.e., if the mother has known viral suppression before delivery 
and is adherent to combination ART), in line with the recommended regimen in other 
resource-advantaged settings [42,43]. In a 2012 survey of national PMTCT guidelines in the 
European region, the vast majority of these guidelines also recommended ZDV 
monotherapy for 4-6 weeks for HIV-exposed infants in most clinical scenarios [44]. 
However, there is variability among countries in the recommended dosing of ZDV. 
Zidovudine dosing information per US guidelines is available for both term and premature 
infants (Table 2); dosing is lower in premature infants per unit of body weight because the 
metabolic pathway to clear ZDV is immature, resulting in a longer half-life [202].
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On the basis of findings from the HPTN 040/P1043 study [23], the US guidelines 
recommend 3 doses of NVP for HIV-exposed infants of mothers who have not received 
combination ART antenatally. The first is recommended to be given at birth, the second is 
given 48 hours after the first dose, and the final dose is given 96 hours after administration 
of the second dose; dosing recommendations are based on birth weight (Table 2). Of note, 
there is limited information about dosing of NVP in premature infants, although a 
pharmacokinetic study of single-dose NVP showed half-lives similar to those of term 
infants, and slower drug clearance in small-for-gestational age premature infants compared 
with those who were of average weight for gestational age [45]. Data about dosing and 
safety for premature infants are lacking for agents other than ZDV and NVP, and 
consultation with a pediatric HIV expert is recommended if their use is being considered in a 
high-risk premature infant [202]. Consultation with a pediatric HIV specialist is also 
recommended in situations where the mother may have received ARV regimens other than 
combination ART, be non-suppressed, or have known resistant virus.
HIV Testing of mothers with unknown HIV status
The US guidelines emphasize routine opt-out rapid HIV testing during the peripartum period 
if the mother's HIV status is not yet known. Most European countries also recommend 
routine maternal testing with an opt-out screening strategy [44]. The US guidelines specify 
that HIV rapid testing should be performed on the mother or infant with appropriate consent 
as soon as possible to allow for PMTCT interventions. The American Academy of Pediatrics 
recommends that rapid testing on the mother, either by saliva or blood, is preferred over 
rapid testing of the infant because of increased sensitivity performance. Establishing an 
infant's HIV exposure status in a timely fashion is the critical first step in providing effective 
neonatal prophylaxis [46].
Intensifying infant prophylaxis in cases with increased risk of HIV 
transmission
A recent case report of very early triple ARV initiation in an HIV-infected infant with 
subsequent lack of virus detection after discontinuation of therapy was believed to have 
resulted in a “functional cure.” While, the virus has returned to detectable levels in this child 
after many months of non-detection [210], the case has sparked increasing discussion about 
the timing of infant HIV PCR testing and triple ARV initiation and latency of the infection 
[47]. Clinical trials are planned to address whether administration of a three-drug regimen in 
therapeutic doses to HIV-exposed high-risk infants could alter the establishment and long-
term persistence of HIV infection [211]. Investigation also is planned to assess the safety of 
such approaches in infants, particularly in the setting of preterm delivery for which 
pharmacokinetic data about most drugs are lacking. These investigations may inform future 
guidelines on neonatal prophylaxis drug selection and duration. Expert consultation on 
managing infants at increased risk for HIV transmission due to suboptimal viral control in 
the mother or high risk labor/delivery should be sought.
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Safety of ARV used as neonatal and infant prophylaxis
The safety and potential toxicities of any regimen are important considerations, and safety 
data are reassuring for the agents most commonly used for prophylaxis among HIV-exposed 
infants for neonatal regimens and during breastfeeding for up to 6 months. Zidovudine 
(ZDV) is the ARV agent with the most safety data in the neonatal population. The most 
common toxicity associated with this agent is anemia or neutropenia, which usually resolves 
by 12 weeks of age [4].
Concerns have been raised regarding possible mitochondrial toxicity associated with 
nucleoside reverse transcriptase inhibitors (NRTIs), including ZDV. Some studies have 
found increased lactate levels, a sensitive but nonspecific marker of possible mitochondrial 
dysfunction, in the blood of HIV-exposed but uninfected neonates treated with ZDV [48]. 
Of note, neonates had been exposed in utero to varying ART regimens, but 3 infants who 
received postnatal ZDV only also exhibited elevated lactate levels. Most of the infants with 
hyperlactatemia were asymptomatic; only two infants were symptomatic, and their 
symptoms disappeared and lactate levels decreased after discontinuation of ZDV. In another 
study, which used more restrictive inclusion criteria for serum lactate measurements due to 
the possibility of artificially high lactate in samples taken under suboptimal conditions, 63 of 
127 HIV-exposed infants on an NRTI regimen (primarily ZDV) developed benign and self-
limited hyperlactatemia [49]. Compared to non-HIV exposed controls, the lactate levels in 
these infants were higher at each of 4 time points (p<0.0001), up to one year of age. 
However, 70% of those infants with initially elevated levels had lactate levels within the 
normal range by age 12 months. No symptoms consistent with hyperlactatemia were 
observed. Hyperlactatemia was significantly associated only with in utero exposure to 
didanosine, which is no longer included in recommended PMTCT regimens for pregnant 
women, and not with other ARV regimens, either during gestation or postnatally. In both 
studies, lactate levels trended toward normal values over time after the conclusion of 6 
weeks of ZDV therapy [48,49]. A study in the Ivory Coast found that increased lactate levels 
were not significantly associated with in utero exposure to ZDV and a 7-day course of 
neonatal ZDV compared with a single-dose NVP regimen [50].
Data are conflicting from studies that looked into symptomatic mitochondrial toxicity 
among HIV-uninfected children with perinatal NRTI exposure. An analysis of the French 
Pediatric Cohort, which included 2644 children exposed to perinatal ARV, found an 18-
month incidence of ‘established’ mitochondrial dysfunction of 0.26% among children 
exposed to ARV (most received either a ZDV regimen or a combined ZDV-lamivudine 
regimen) [51]. Established cases were shown to have a deficit in the mitochondrial 
respiratory chain and/or characteristic histological findings. Of note, one case was seen in an 
infant who was exposed to prenatal, but not neonatal, ART. No cases of possible 
mitochondrial dysfunction were found among the 1748 children in the cohort without 
perinatal ART exposure. While still a very rare outcome, the 0.26% incidence in this study 
is much greater than the 0.01% incidence in the general population. After a preliminary 
report [52] of these findings was published, a review of the US data from the Perinatal AIDS 
Collaborative Transmission Study (n=1954) was initiated and did not find any evidence 
indicating that uninfected infants exposed to perinatal NRTIs had symptoms of 
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mitochondrial dysfunction or that any deaths among the cohort could be attributed to this 
cause [53]. A review of 5 US cohorts (combined population of over 10,000 children exposed 
to NRTIs) also found no indication that perinatal ARV exposure was associated with death 
from mitochondrial dysfunction or from sudden infant death syndrome [54]. A later analysis 
of the data from the European Collaborative Study, which included 1008 infants exposed to 
ART perinatally (ZDV therapy was the most common neonatal regimen), also found no 
association of NRTI exposure with clinical manifestations suggestive of mitochondrial 
dysfunction [55].
Overall, the evidence on the possibility of mitochondrial toxicity from ZDV given 
postnatally is equivocal, and even supportive studies found a low absolute incidence of 
mitochondrial dysfunction.
There are limited safety data for multiple-agent ARV regimens for HIV-exposed infants; 
however, the HPTN 040/P1043 study showed that a three-agent combination of zidovudine 
for 6 weeks, plus nelfinavir and lamivudine for 2 weeks, had higher rates of neutropenia 
compared with a two-agent regimen of zidovudine for 6 weeks plus three doses of 
nevirapine or ZDV alone [23].
Nevirapine has been associated with increased risk of hepatotoxicity among adults, as well 
as rash and hypersensitivity reactions; however, these have not been prominent among 
infants. In the BAN study, 6 of 39 mothers had a hypersensitivity reaction to NVP, but only 
16 of 852 infants on an extended daily NVP regimen for up to 28 weeks exhibited 
hypersensitivity [27]. Extended dosing of nevirapine among breastfeeding infants for up to 6 
months was not associated with increases in adverse events versus a 6-week regimen in 
HPTN 046 [39].
There is very limited or no information on neonatal safety or dosing for other ARV agents 
[202]; and where neonatal dosing has been studied, efficacy data are not yet available [56]. 
The FDA recommends that ritonavir-boosted lopinavir should not be administered before a 
postmenstrual age of 42 weeks and a minimum postnatal age of 14 days; this label change 
was in response to reports of severe toxicity among preterm neonates, including heart block 
and other forms of cardiac toxicity [212]. Among term infants, use of a lopinavir-ritonavir 
regimen was associated with asymptomatic and transient adrenal dysfunction, which was not 
seen among infants treated with a ZDV-based regimen; this was most pronounced among 
infants whose mothers had also received lopinavir-ritonavir or a similar combination therapy 
as ART late in their pregnancies [57].
Immunoprophylaxis
Although much progress has been made in PMTCT using ARV regimens, additional 
prevention methods are needed. Modeling has estimated that even with 90% coverage of 
recommended ARV therapy among pregnant women, a 50% reduction in HIV incidence 
among reproductive-age women, and the prevention of all unintended pregnancies, the goal 
of virtual elimination of MTCT would still not be met in the 25 countries with the largest 
populations of HIV-infected pregnant women [58]. In addition, a recent meta-analysis 
showed that only 72% of pregnant women are more than 80% adherent to their ART 
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regimen, and that adherence is lower during the postpartum period [59]. There is evidence 
that maternal adherence may be associated with correct administration of the infant's 
antiretrovirals. One study showed that mothers who adhered to their own ART regimens 
during pregnancy were more likely to have adhered to the infant's regimen after birth [60]. 
These and other challenges emphasize that although current strategies are making great 
strides, additional tools are needed [61]. One potential adjunct prevention modality is 
immunoprophylaxis.
Immunoprophylaxis is classified as either active, by vaccination, or passive, by infusion of 
antibodies. Much effort has been directed toward vaccine development, and some potential 
vaccines have completed trials, whereas others are currently in progress. In the United 
States, trials such as that of the ALVAC-HIV vCP 1452 vaccine with and without a subunit 
rgp 120 envelope boost showed that even in the presence of potentially attenuating maternal 
antibodies, infants can mount an immune response to HIV vaccine, with antibodies 
produced by some subjects showing neutralizing activity towards HIV homologous to the 
vaccine strain [62]. The first pediatric HIV vaccine trial in Africa has been completed in 
Uganda, and data demonstrated the safety and feasibility of the vaccine studied 
(ALVACHIV vCP1521) [63], although only low levels of cellular immune responses were 
generated, and no neutralizing antibodies were detected [64]. PedVacc001 studied the safety 
and immunogenicity of the MVA.HIVA vaccine in Gambia among 20-week-old infants of 
HIV-uninfected mothers. No severe adverse events occurred during the trial, and the vaccine 
did not interfere with antibody induction to the standard childhood vaccines. However, only 
9% of vaccinated infants demonstrated an HIV-1-specific T cell response [65]. The most 
promising vaccine study so far, a trial of ALVAC-HIV vCP 1521 among adults in Thailand 
that incorporated boosting with 2 recombinant envelope proteins, found that the vaccine had 
31% efficacy (95% CI: 1.1–51.1%; P = .04) [66].
Passive immunoprophylaxis is accomplished through the administration of monoclonal 
antibodies designed to bind to HIV and reduce its infectivity in the recipient; unlike 
vaccination, it does not induce the recipient to produce his or her own immune response, so 
the length of effect depends on the half-life of the antibody administered. In one study, HIV 
hyperimmune globulin (HIVIGLOB) was administered intravenously to mother-infant pairs 
in Uganda—to the mother at 36–38 weeks’ gestation and to the infant within 18 hours of 
birth. Single-dose nevirapine therapy was administered both to the intervention and the 
control groups. Results found no difference in safety between the two groups; however, 
there was also no significant difference in effectiveness for the prevention of MTCT [67]. 
Other antibodies are under investigation, particularly broadly neutralizing antibodies, which 
target well-conserved sites on the HIV virus, such as the CD4 binding site [68]. One such 
antibody, VRC01, has been shown to protect infant macaques from oral SHIV challenge in 
one small study, and a phase 1 study among human infants is planned for further evaluation 
of this potential prophylactic treatment [69, 213].
Expert commentary & five-year view
There has been a great deal of progress and many developments in the field of preventing 
MTCT of HIV; the use of extended ARV prophylaxis during gestation, labor and delivery, 
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and, for resource-limited settings, during breastfeeding has certainly transformed the field. 
Now, envisioning elimination of pediatric HIV infection has become possible. However, 
even with the use of best approaches, including extended combination ARV regimens and 
optimal infant delivery practices, a residual small risk of transmission exists (approximately 
1% for perinatal transmission, 3%–5% for breastfeeding transmission). Several questions 
and areas for research remain. The short- and long-term safety of ARV regimens for mothers 
and infants during gestation and breastfeeding, including drugs of newer ARV classes, needs 
to be continuously monitored. It is perhaps surprising that there is still very limited 
pharmacokinetic and dosing information for most ARV drugs for infants, (including widely 
used agents, such as nevirapine and protease inhibitors), particularly infants who are 
premature or of low-birth weight; such studies are urgently needed. Development of 
resistance (incidence and patterns) among infants who become HIV-infected despite 
prophylaxis also needs to be carefully monitored, as it may affect their treatment options. 
The role of new ARV drugs needs to be investigated; such agents may offer distinct 
advantages for PMTCT, either by acting on different stages of the viral cycle, or because of 
unique pharmacokinetic and pharmacodynamic properties (e.g., integrase inhibitors). 
Pharmacogenetic studies are another area that will develop during the next few years, as it 
appears that genetic polymorphisms may underlie individual differences in the metabolism 
of some ARV drugs (e.g., nonnucleoside reverse transcriptase inhibitors (NNRTI), as well 
as hypersensitivity reactions to others (e.g., abacavir and possibly NNRTI). Single 
nucleotide genetic polymorphisms may also underlie increased susceptibility to HIV 
infection for some infants. In the future, genome-wide association studies will pave the way 
for personalized pharmacotherapy and dosing, and for identification of infants at higher risk 
who can be targeted for intensified prophylaxis. Whether combined maternal and infant 
prophylaxis for the duration of breastfeeding is advantageous for reducing residual 
transmission, when balanced against risks of ARV exposure, and whether such an approach 
might also be acceptable in a resource-rich setting, offers a new research direction. More 
research on the immune aspects of protection needs to be pursued; indeed we still do not 
understand why a majority of exposed infants escape HIV infection. Such research could 
pave the way for immune strategies of protection (passive immunoprophylaxis or a vaccine) 
that could be given in combination with ARV strategies to maximize benefit and minimize 
duration of ARV exposure. Addressing other maternal and infant co-infections should not be 
overlooked as they contribute to maternal and infant morbidity and mortality and increase 
the risk of infant HIV infection; (such infections include herpes simplex virus, 
cytomegalovirus, or malaria) [70]. In addition, approaches to promote infant intestinal health 
(exclusive breastfeeding, use of rotavirus vaccine, and possibly probiotics) might be 
beneficial in further reducing HIV transmission through breastfeeding because damage to 
the mucosal barrier, either caused by food insults, gastrointestinal infections, or receipt of 
broad-spectrum antibiotics, is correlated with increased risk of immune activation and infant 
HIV infection [71]. Whether breastfeeding with ARV prophylaxis is an acceptable strategy 
in resource-rich settings for the HIV-infected women who strongly wish to breastfeed their 
infants has not been evaluated; a formal assessment of its risk-benefit ratio deserves more 
study. Finally, the role of early aggressive treatment for all HIV-exposed infants in 
interrupting establishment of infection is an avenue that holds promise for the future of 
pediatric HIV infection and may well transform the concept of neonatal prophylaxis.
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Translating research into successful implementation is still challenging in many parts of the 
world. Limited access to ARV medications in many settings because of costs and lack of 
resources or political will, poor health infrastructure, lack of integration of HIV prevention 
and treatment with maternal and reproductive health services, and social reasons, such as 
stigma, are still major obstacles to ARV scale-up among pregnant women. Even more 
challenging is implementation of neonatal ARV prophylaxis. Data from WHO show that 
worldwide, less than half of infants born to HIV-infected mothers received ARV 
prophylaxis in 2011 [214]. Now that plans are in place for Option B+ roll out in many parts 
of the world, it is important to evaluate women's long-term acceptance of and adherence to 
life-long ART, particularly for those who are at earlier stages of their HIV disease, as well 
as to examine the effects of ARV and adherence on maternal and infant outcomes. Linking 
HIV prevention, care and treatment services with family planning, antenatal and child and 
maternal health services, and building the health infrastructure required for such programs, 
can aid in achieving prophylaxis and treatment goals and lead to the elimination of pediatric 
HIV infection worldwide.
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• Significant reductions in the rate of mother-to-child transmission of HIV have 
been achieved with the use of ARV regimens during pregnancy, labor and 
delivery, and postnatally to the infant. However, in less advantaged settings, 
pediatric HIV infection is an ongoing epidemic caused by challenges in 
identifying HIV-infected mothers and implementing preventive strategies.
• Neonatal prophylaxis is an important component of PMTCT of HIV when the 
mother has received ARV medications antenatally, and it's absolutely critical 
when the mother has not received ARV prophylaxis before delivering the infant.
• The recommended regimen for neonatal prophylaxis in the United States is 4–6 
weeks of ZDV depending on gestational age at birth and maternal ART status. 
In addition, three doses of NVP in the first week of life are recommended if the 
mother did not receive antepartum combination ART.
• The WHO recommendation for neonatal prophylaxis is 6 weeks of NVP for 
breastfed infants and 4–6 weeks of NVP or ZDV for non-breastfed infants. The 
recommended duration of infant ARV prophylaxis is extended on the basis of 
varying clinical scenarios. For mothers who are not on lifelong ART and are 
breastfeeding, the recommendation is to continue ART until 1 week after 
breastfeeding ends.
• ARV prophylaxis regimens provided to the mother or to the infant during 
breastfeeding are effective at reducing the risk of postnatal transmission of HIV 
and are key strategies in settings where breastfeeding is the safest infant feeding 
option.
• Current WHO guidelines focus on strategies for use of ARV regimens by the 
mother throughout the duration of pregnancy, labor and delivery, and 
breastfeeding, but there are many questions about the long-term safety, 
effectiveness, and acceptability of these options.
• The short- and long-term safety of ARV regimens for mothers and infants 
during gestation and breastfeeding, including drugs of newer ARV classes, 
needs to be continuously monitored.
• Although much progress has been made in identifying effective ARV regimens 
for PMTCT, additional prevention methods are needed to eliminate pediatric 
HIV infections worldwide: prevention of HIV infection in women, prevention of 
unintended pregnancies, provision of appropriate ARV regimens, and care to all 
mothers and infants, and, hopefully, the development of immunoprophylaxis as 
an adjunct strategy (active or passive immunization).
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Table 1
WHO Programme Options for ART for PMTCT, 2013
National PMTCT 
programme option
Pregnant and breastfeeding women with HIV HIV-exposed infant
Use lifelong ART for all 
pregnant and breastfeeding 
women (“Option B+”)
Regardless of WHO clinical stage or CD4 cell 
count
Breastfeeding Replacement feeding
Initiate ART and maintain after delivery and 
cessation of breastfeeding
6 weeks of infant 
prophylaxis with 
once-daily NVP
4-6 weeks of infant prophylaxis 
with once-daily NVP (or twice-
daily AZT)
Use lifelong ART only for 
pregnant and breastfeeding 





Not eligible for 
treatment 
a
Initiate ART and 
maintain after 
delivery and cessation 
of breastfeeding 
b
Initiate ART and stop 






Reproduced, with the permission of the publisher, from the Consolidated guidelines on the use of antiretroviral drugs for treating and preventing 
HIV infection. Recommendations for a public health approach June 2013. Geneva, World Health Organization, 2013 (Table 7.3, Page 101 http://
apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf, accessed 07 March 2014)”
Abbreviations: PMTCT: Prevention of Mother-to-Child Transmission of HIV; ART: Antiretroviral Therapy; WHO: World Health Organization; 
NVP: Nevirapine; AZT: Zidovudine
a
CD4 count ≤500 cells/mm3 or clinical stage 3 or 4 disease at the time of ART initiation or in accordance with national guidelines.
b
Patients who develop clinical or laboratory criteria indicating failure during pregnancy or the breastfeeding period should be assessed for second-
line therapy.
c
In the case of breastfeeding, stop ART one week after breastfeeding ends. In the case of replacement feeding, stop ART after delivery.
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Table 2
US Guidelines for dosing neonatal prophylaxis in infants born to HIV-infected mothers
Zidovudine (ZDV) dosing for neonates for the prevention of perinatal transmission of HIV
*
Gestational age at birth Dosing Duration
>35 weeks PO: 4mg/kg/dose twice daily
Birth through 4-6 weeks
**
IV: 3mg/kg/dose every 12 hours
≥30 to <35 weeks PO: 2 mg/kg/dose every 12 hours, advanced to 3 mg/kg/dose every 12 hours at age 
15 days
Birth through 6 weeks
IV: 1.5mg/kg/dose every 12 hours, advanced to 2.3 mg/kg/dose every 12 hours at age 
15 days
<30 weeks PO: 2 mg/kg/dose every 12 hours, advanced to 3 mg/kg/dose every 12 hours after age 
4 weeks
Birth through 6 weeks
IV: 1.5 mg/kg/dose IV every 12 hours, advanced to 2.3 mg/kg/dose IV every 12 
hours after age 4 weeks
Nevirapine (NVP) dosing for neonates (recommended in addition to ZDV, as shown above, for HIV-exposed infants of women who did 
not receive antepartum combination ART)
Birth weight Dosing Duration
1.5-2 kg 8 mg/dose PO 3 doses within the first week of life
Dose 1: Administer as soon as possible after delivery, within 
48 hours of birth
>2 kg 12 mg/dose PO Dose 2: 48 hours after dose 1
Dose 3: 96 hours after dose 2
Adapted from Panel on Treatment of HIV-infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of 
Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the 
United States. p. E-12 “Recommended Neonatal Dosing for Prevention of Perinatal Transmission of HIV” [202].
*
For all infants, give first dose as soon as possible after birth, preferably within 6-12 hours of delivery. Use IV dosing if infant is unable to tolerate 
PO medication.
**
A 6-week course of neonatal ZDV is generally recommended. A 4-week course may be considered for infants born at ≥35 weeks when the 
mother has received standard ART during pregnancy with consistent viral suppression, and there are no concerns regarding maternal adherence.
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